AOD-9604 vs Frag 176 191: Comparing the Indexed Record
Researchers comparing AOD-9604 and Frag 176 191 are usually resolving one question: which compound the published record actually supports for the model in front of them.
Side-by-side research profile
| Parameter | AOD-9604 | Frag 176 191 |
|---|---|---|
| PubMed indexed records | 16 | 1 |
| Registered studies (ClinicalTrials.gov) | 0 | 0 |
| Literature depth | Emerging | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
AOD-9604 in the indexed record
The literature on AOD-9604 is a limited body of work: 16 PubMed-indexed records with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
Frag 176 191 in the indexed record
The literature on Frag 176 191 is a limited body of work: 1 PubMed-indexed records with no registered studies currently listed on ClinicalTrials.gov.
Publications carrying this compound include J Sports Med Phys Fitness.
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — J Sports Med Phys Fitness, 2026. PMID: 41880199
How the literature differs
The indexed record is not symmetrical between these two compounds. AOD-9604 carries 15 more indexed records than Frag 176 191, which means published methodology, characterisation data and replication attempts are more readily located for AOD-9604. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
AOD-9604 and Frag 176 191 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Frag 176 191 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Selecting between them for a study design
AOD-9604 and Frag 176 191 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (AOD-9604) generally offers more methodological precedent.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Which of AOD-9604 or Frag 176 191 has more published research?
AOD-9604, with 16 indexed PubMed records against 1.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- AOD-9604 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.